This Phd manuscript deals with the modeling of the HIV-1 protease (HIV-1 PR), using a variety of computational chemistry methods. Two specific models have been developed. The first one corresponds to the active site of the enzyme in complex with the substrate. A comparative study based on several theoretical methods enables to show that the hybrid approach QM/MM-BLYP/PW:AMBER is a very good compromise between accuracy and computational cost. The second model represents a complex between the protein and an amino-aldehyde inhibitor, described at the QM/MM-BLYP/PW:AMBER level. Our calculations highlight some destabilizing interactions between the enzyme and the inhibitor. These results suggest the development of alternative amino-aldehyde inhi...
The efficiency of protease inhibiting drugs is hampered by the rapid emergence of protease variants....
Human immunodeficiency virus type 1 protease (HIV-1 PR) is an essential enzyme in the HIV-1 life cy...
HIV-1 aspartic protease (PR) is a promising target for acquired immunodeficiency syndrome (AIDS) the...
Human Immunodeficiency Virus (HIV) is the causative agent of the pandemic disease Acquired Immune De...
This report describes a method for the assessment of inhibitor binding affinities to wild type HIV-1...
The Lamarckian genetic algorithm of AutoDock 3.0 has been used to dock 27 3(S)-amino-2(S)-hydroxyl-4...
HIV-1 protease is one of the main therapeutic targets in HIV. However, a major problem in treatment ...
Multiple Quantitative Structure-Activity Relationship (QSAR) analysis is widely used in drug discove...
HIV-1 protease is one of the main therapeutic targets in HIV. However, a major problem in treatment ...
<div><p>HIV-1 protease is one of the main therapeutic targets in HIV. However, a major problem in tr...
Despite the fact that HIV-Protease is an over 20 years old target, computational approaches to ratio...
Starting from the X-ray structure of an HIV-1 protease inhibitor complex we performed Molecular Dyna...
AbstractThe mechanism of the first steps of the reaction catalyzed by HIV-1 protease was studied thr...
The efficiency of protease inhibiting drugs is hampered by the rapid emergence of protease variants....
Human immunodeficiency virus type 1 protease (HIV-1 PR) is an essential enzyme in the HIV-1 life cy...
The efficiency of protease inhibiting drugs is hampered by the rapid emergence of protease variants....
Human immunodeficiency virus type 1 protease (HIV-1 PR) is an essential enzyme in the HIV-1 life cy...
HIV-1 aspartic protease (PR) is a promising target for acquired immunodeficiency syndrome (AIDS) the...
Human Immunodeficiency Virus (HIV) is the causative agent of the pandemic disease Acquired Immune De...
This report describes a method for the assessment of inhibitor binding affinities to wild type HIV-1...
The Lamarckian genetic algorithm of AutoDock 3.0 has been used to dock 27 3(S)-amino-2(S)-hydroxyl-4...
HIV-1 protease is one of the main therapeutic targets in HIV. However, a major problem in treatment ...
Multiple Quantitative Structure-Activity Relationship (QSAR) analysis is widely used in drug discove...
HIV-1 protease is one of the main therapeutic targets in HIV. However, a major problem in treatment ...
<div><p>HIV-1 protease is one of the main therapeutic targets in HIV. However, a major problem in tr...
Despite the fact that HIV-Protease is an over 20 years old target, computational approaches to ratio...
Starting from the X-ray structure of an HIV-1 protease inhibitor complex we performed Molecular Dyna...
AbstractThe mechanism of the first steps of the reaction catalyzed by HIV-1 protease was studied thr...
The efficiency of protease inhibiting drugs is hampered by the rapid emergence of protease variants....
Human immunodeficiency virus type 1 protease (HIV-1 PR) is an essential enzyme in the HIV-1 life cy...
The efficiency of protease inhibiting drugs is hampered by the rapid emergence of protease variants....
Human immunodeficiency virus type 1 protease (HIV-1 PR) is an essential enzyme in the HIV-1 life cy...
HIV-1 aspartic protease (PR) is a promising target for acquired immunodeficiency syndrome (AIDS) the...